<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742972</url>
  </required_header>
  <id_info>
    <org_study_id>PST010</org_study_id>
    <nct_id>NCT04742972</nct_id>
  </id_info>
  <brief_title>Prostate PMSABR Study</brief_title>
  <official_title>PSMA-PET Guided Stereotactic Ablative Body Radiotherapy for Oligometastasis in Metastatic Castration-resistant Prostate Cancer (mCRPC) With Progression on Enzalutamide (PMSABR Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Darren Poon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigator aim to evaluate the role of PMSA-PET guided SABR on&#xD;
      progression free survival (PFS) in patients with oligoprogressive mCRPC with Enzalutamide.&#xD;
      The potential improvement in PFS with SABR while continuing the initial-responding&#xD;
      Enzalutamide is potentially benefiting to patients in terms of overall disease control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The 6-month progression-Free Survival rate</measure>
    <time_frame>up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control rate of the SABR-treated oligometastasis at 6 months after SABR</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control rate of the SABR-treated oligometastasis at 6 months after SABR based on the PERCIST criteria</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL (EORTC QLQ-C30)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next systemic treatment</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of participants with treatment-related adverse event as assessed by CTCAE v4.0</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients in both arms who have AR-V7 (CTCs)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>SABR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SABR</intervention_name>
    <description>SABR is delivered to all sites of oligometastasis with continuation of Enzalutamide. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in SOC Arm.</description>
    <arm_group_label>SABR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SOC</intervention_name>
    <description>Three options:&#xD;
Continuation of Enzalutamide&#xD;
Observation&#xD;
Switch to next line treatment</description>
    <arm_group_label>SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological confirmation of prostate adenocarcinoma&#xD;
&#xD;
          -  Evidence of stage IV disease (as defined by AJCC criteria) on previous bone, CT,&#xD;
             and/or MRI scan&#xD;
&#xD;
          -  Ongoing ADT with a gonadotropin-releasing hormone (GnRH) analogue or bilateral&#xD;
             orchiectomy (ie, surgical or medical castration) confirmed by testosterone level ≤&#xD;
             1.73 nmol/L (50 ng/dL) at the screening visit&#xD;
&#xD;
          -  ECOG performance score 0-2&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  History/physical examination within 2 weeks prior to registration&#xD;
&#xD;
          -  Able to sign informed-consent&#xD;
&#xD;
          -  Patient with mCRPC who received Enzalutamide during the past 6-8 weeks and must have&#xD;
             been delivered for a total of at least 3 months with an initial ≥50% decline of PSA&#xD;
             from baseline.&#xD;
&#xD;
          -  Documented disease progression with Enzalutamide as defined by PCWG3 with at least one&#xD;
             of the followings:&#xD;
&#xD;
               1. PSA progression: defined by PSA increase that is ≥ 25% and ≥ 2 ng/mL above the&#xD;
                  nadir. A minimum of 2 rising PSA levels with an interval of ≥ 1 week between each&#xD;
                  determination.&#xD;
&#xD;
               2. Radiographic disease progression in soft tissue based on RECIST 1.1 criteria.&#xD;
                  Participants whose disease spread is limited to regional pelvic lymph nodes (N1)&#xD;
                  measuring at least 2 cm in short axis will be considered eligible.&#xD;
&#xD;
               3. Radiographic disease progression in bone defined as appearance of 2 or more new&#xD;
                  bone lesions on bone scan&#xD;
&#xD;
          -  A maximum of 5 extracranial metastases in any organ system (except brain), with ≤ 4&#xD;
             tumours within any given organ system, confirmed with PSMA PET-CT scan&#xD;
&#xD;
          -  All sites of oligometastasis can be safely treated with SABR&#xD;
&#xD;
          -  Adequate baseline organ function to allow SABR to all relevant targets&#xD;
&#xD;
          -  Participants already receiving agents for the management of skeletal-related events&#xD;
             (SREs) are allowed to continue with anti-bone resorptive therapy (including, but not&#xD;
             limited to bisphosphonate or receptor activator of nuclear factor kappa ligand&#xD;
             inhibitor) if on stable dose for more than 28 days prior to treatment arm assignment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with active cancer other than prostate cancer and non-melanoma skin cancer.&#xD;
&#xD;
          -  Prior treatment with docetaxel, another chemotherapy agent or second generation&#xD;
             hormonal therapy (e.g. abiraterone acetate or enzalutamide) for metastatic&#xD;
             castration-resistant prostate cancer. Prior docetaxel, abiraterone acetate or&#xD;
             enzalutamide for metastatic hormone-sensitive prostate cancer is allowed if ≥ 12&#xD;
             months elapsed from last dose of these treatments.&#xD;
&#xD;
          -  PSA at inclusion &gt;20 ng/ml&#xD;
&#xD;
          -  Serum creatinine and total bilirubin &gt; 3 times the upper limit of normal&#xD;
&#xD;
          -  Liver Transaminases &gt; 5-times the upper limit of normal&#xD;
&#xD;
          -  Unstable angina and/or congestive heart failure requiring hospitalization, transmural&#xD;
             myocardial infarction within the last 6 months, acute bacterial or fungal infection&#xD;
             requiring intravenous antibiotics, chronic obstructive pulmonary disease exacerbation&#xD;
             or other respiratory illness requiring hospitalization or precluding study therapy at&#xD;
             the time of registration&#xD;
&#xD;
          -  Patients with oligometastases that have been previously treated with SABR.&#xD;
&#xD;
          -  Serious medical comorbidities precluding radiotherapy, such as ataxia-telangiectasia&#xD;
             or scleroderma. For patients with oligoprogressive lesions in the lung or thorax, this&#xD;
             includes interstitial lung disease&#xD;
&#xD;
          -  Clinical or radiological evidence of spinal cord compression or tumor within 1.5mm of&#xD;
             spinal cord on MRI&#xD;
&#xD;
          -  Malignant pleural effusion&#xD;
&#xD;
          -  Malignant peritoneal disease&#xD;
&#xD;
          -  Intra-cranial metastases&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Darren MC POON, FHKCR</last_name>
    <phone>3505 2128</phone>
    <email>mc_poon@clo.cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane KOH, RN</last_name>
    <phone>3505 1142</phone>
    <email>jane@clo.cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darren MC POON, FHKCR</last_name>
      <phone>3505 2128</phone>
      <email>mc_poon@clo.cuhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Jane KOH, RN</last_name>
      <phone>3505 1142</phone>
      <email>jane@clo.cuhk.edu.hk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Darren Poon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

